Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection

Table 1 Demographic characteristics of Helicobacter pylori infected patients in probiotic pre-treated, post-treated and standard therapy groups (per protocol set, n = 228)

	POCA (n = 76)	OCAP (n = 74)	OCA (n = 78)	P value
Age, yr	44.9 ± 13.8	48.2 ± 12.2	48.0 ± 13.3	0.2271
Sex (male %)	32 (42.1)	26 (35.1)	33 (42.3)	0.5942
H. pylori test (pre-therapy)				0.9492
13C-UBT	13 (17.1)	10 (13.5)	14 (17.9)
14C-UBT	23 (30.3)	24 (32.4)	21 (26.9)
RUT	34 (44.7)	34 (45.9)	34 (43.6)
HE	6 (7.9)	6 (8.1)	9 (11.5)
H. pylori test (post-therapy)				0.8792
13C-UBT	38 (50.0)	34 (45.9)	38 (48.7)
14C-UBT	38 (50.0)	40 (54.1)	40 (51.3)
Mean follow-up time, d	58.2 ± 15.5	44.9 ± 12.3	43.2 ± 11.0	< 0.0011

Data are presented as mean ± SD or n (%).

¹Student’s t test;

²Fisher’s exact test. H. pylori: Helicobacter pylori; UBT: Urea breath test; RUT: Rapid urease test; HE: Hematoxylin and eosin stain; POCA: Probiotic pre-treated group; OCAP: Probiotic post-treated group; OCA: Standard therapy group.